BiotechTube

NP-015

Phase 1Completed
0 watching 0 views this weekπŸ’€ Quiet
25
Hype Score

Development Stage

βœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Symptoms of Inhalational Anthrax

Conditions

Symptoms of Inhalational Anthrax

Trial Timeline

Jul 1, 2007 β†’ Sep 1, 2008

NCT ID
NCT00448253

About NP-015

NP-015 is a phase 1 stage product being developed by Emergent BioSolutions for Symptoms of Inhalational Anthrax. The current trial status is completed. This product is registered under clinical trial identifier NCT00448253. Target conditions include Symptoms of Inhalational Anthrax.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00448253Phase 1Completed

Competing Products

20 competing products in Symptoms of Inhalational Anthrax

See all competitors
ProductCompanyStageHype Score
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
52
SolifenacinAstellas PharmaPre-clinical
23
Tamsulosin + SolifenacinAstellas PharmaApproved
85
Vesitirimβ„’ (Solifenacin)Astellas PharmaPre-clinical
23
Mirabegron + PlaceboAstellas PharmaPhase 2
52
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
77
tamsulosin hydrochloride + solifenacin succinate + PlaceboAstellas PharmaPhase 2
52
Tamsulosin + SolifenacinAstellas PharmaApproved
85
Tamsulosin OCASAstellas PharmaApproved
85
fezolinetant + placeboAstellas PharmaPhase 3
77
NaloxegolKyowa KirinPhase 1
33
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiolEli LillyPhase 2
52
Atomoxetine Hydrochloride + Sertraline + PlaceboEli LillyApproved
85
MK-6913 + 17-Ξ² estradiol + Placebo to MK-6913 + Placebo to 17-Ξ² estradiol + MK-6913 25 mgMerckPhase 2
52
Esmirtazapine + PlaceboMerckPhase 3
77
Comparator: Estrace 0.5 mg + Comparator: Estrace 2 mg + Comparator: PlaceboMerckPhase 1
33
RivastigmineNovartisPhase 3
77
Mycophenolate SodiumNovartisApproved
85
Erenumab + PlaceboAmgenPhase 1
32
IdelalisibGilead SciencesPre-clinical
22

Other Products from Emergent BioSolutions

Blood sample collectionApproved
77
AVA + Raxibacumab + DiphenhydramineApproved
77
Vaccination with ACAM2000Approved
77
Sample CollectionApproved
77
AV7909 + BioThraxPhase 3
69